sign in sign up
<<
Home , Durvalumab, Nimotuzumab, Oleclumab, Varlilumab

Current Active Clinical Trials - Roswell Park Cancer Institute

Primary Site Protocol Principal Investigator Unknown Sites P-34916 Almyroudis N Breast I-120807 Ambrosone C Breast I-166909 Ambrosone C Lip, Oral Cavity and Pharynx I-33616 Arshad H Myeloid and Monocytic Leukemia PH-259514 Wang E Lip, Oral Cavity and Pharynx I-67918 Arshad H Myeloid and Monocytic Leukemia N-43417 Balderman S Other Hematopoietic N-50517 Balderman S Multiple I-40916 Balderman S Leukemia, other NCG-265014 Bambach B Other Hematopoietic N-42816 Bambach B Other Hematopoietic N-71918 Bambach B Multiple Sites; Leukemia, other PH-271115 Bambach B

Myeloid and Monocytic Leukemia; Leukemia, I-82019 Baron J other Non-Hodgkin's Lymphoma NCG-288416 Barth M Non-Hodgkin's Lymphoma I-238713 Barth M Leukemia, other I-62318 Barth M

Leukemia, other PH-276215 Becker J Colon; Rectum P-70418 Boland P

Page 1 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Date Opened Date Closed Study Phase 06/05/2017 04/25/2019 N/A 12/26/2007 N/A 03/16/2010 01/21/2019 N/A 03/30/2017 10/02/2019 II 06/30/2015 02/26/2019 I/II 01/17/2019 II 04/26/2018 04/29/2019 III 03/14/2018 II 12/07/2017 II 04/09/2015 03/23/2018 N/A 12/21/2017 II 10/11/2018 N/A 08/03/2016 III

03/19/2019 01/15/2020 N/A

02/16/2017 II 01/08/2014 08/27/2019 II 02/08/2019 N/A

06/23/2016 02/01/2019 N/A 01/16/2019 08/05/2019 N/A

Page 2 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Title Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles The Women's Circle of Health Study DNA Methylation: A Mechanism for Aggressive Breast Cancers in African American Women? A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) with PDT versus Standard of Care Surgery for Patients with T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell A Randomized, Multi-Center Phase 2 Trial with a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy versus SoC Therapy alone for the Treatment of Patients with Locally Advanced or Recurrent . BMT CTN 1506; A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML (BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS. (PBMTC 13-TLEC) Natural History and Biology of Long-Term Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies BMT CTN 1502 Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP) (ACCL1633) The Effectiveness of Lactobacillus plantarum in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) (ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Asparaginase Evaluation of patient reported impact of a clinical pharmacist on the management of inhibitors in a leukemia clinic

(COG ANHL12P1) A Randomized Phase II Trial of (SGN35, NSC# 749710), or (NSC# 749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117 Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma Matched (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome

A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components Evaluation of the Performance of the Clinical Genomics Colvera Test in the Detection of Disease Recurrence in Patients Diagnosed with Colorectal Cancer- NOVA

Page 3 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Esophagus; Stomach I-169210 Boland P Breast I-60217 Bonaccio E Unknown Sites I-75818 Bouchard E Unknown Sites I-288716 Bouchard E Unknown Sites I-77618 Bouchard E Esophagus I-57817 Buas M Colon I-74018 Case A Prostate I-43017 Chatta G Prostate N-79118 Chatta G Multiple Sites; Bladder I-69518 Chatta G Prostate N-43917 Chatta G Prostate I-63418 Chatta G Multiple I-77218 Chatta G Prostate I-287816 Chatta G Prostate I-78118 Chatta G Prostate I-72118 Chatta G Prostate I-77318 Chatta G Other Urinary P-48417 Chatta G Prostate P-36616 Chatta G Prostate P-44017 Chatta G Bladder P-62418 Chatta G Prostate P-62518 Chatta G

Page 4 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

09/22/2010 06/24/2014 II 10/18/2018 N/A 12/20/2018 N/A 06/08/2017 N/A 01/03/2019 N/A 01/18/2018 N/A 06/26/2019 II 02/12/2018 N/A 02/19/2019 III 04/10/2019 II 06/29/2017 01/23/2019 II/III 06/07/2019 I/II 06/20/2019 11/25/2019 II 04/03/2017 I/II 07/11/2019 III 01/03/2019 N/A 11/29/2019 II 06/27/2018 10/10/2019 III 08/02/2017 12/11/2019 II 10/04/2017 01/18/2019 III 08/03/2018 04/10/2019 II 09/05/2018 I/II

Page 5 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates Photoacoustic Imaging of Human Breast Enhancing infrastructure for Native American and Rural Cancer Control Research Capacity at Roswell Park Comprehensive Cancer Center The Influence of Social Network Size, Composition and Function on Psychological Outcomes of Pediatric Cancer Caregiving: Relationships across Time and around Periods of Distress A novel parenting skills intervention to improve medication adherence in pediatric cancer The Roswell Park Barrett's and Esophageal Adenocarcinoma Registry (RP-BEAR) Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center IRONMAN: International Registry for Men with Advanced Prostate Cancer (S1802) Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (CITN-14) Randomized Phase II study of (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma (NRG-GU002) Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel Phase Ib/II Study of Enzalutamide with (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) with , in Subjects Who Have Failed -based Chemotherapy with Locally Advanced (Unresectable) or Metastatic Transitional Cell Cancer (TCC) of the Urothelium Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-induced Obese Frailty in Survivors of Advanced Prostate Cancer Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen A Phase 3, Open-label, Randomized Study of Combined with , or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency TRITON3:A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Page 6 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Multiple Sites P-33316 Chatta G Multiple P-77918 Chatta G Other Hematopoietic I-286216 Chen G Unknown Sites I-273815 Chen G Other Hematopoietic I-53817 Chen G Unknown Sites I-207511 Chen G Unknown Sites I-270115 Chen G Lung N-61417 Chen H Lung NCG-263614 Chen H Lung N-19-04259 Chen H Lung N-545819 Chen H Lung NCG-260614 Chen H Lung I-225512 Chen H Lung I-42316 Chen H Myeloid and Monocytic Leukemia P-31916 Chen H P-81618 Chen H

Lung P-50817 Chen H Lung PH-271315 Chen H Unknown Sites I-254114 Chodon T , Skin I-278415 Chowdhry V Unknown Sites I-38416 De Wald R

Page 7 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

05/17/2017 05/06/2019 I/II 06/20/2019 11/20/2019 II 12/13/2016 05/22/2019 N/A 12/16/2015 N/A 05/01/2018 N/A 02/04/2013 N/A 04/04/2016 N/A 03/08/2018 Early Phase I 04/21/2016 III 05/08/2019 II/III 12/03/2019 II 04/06/2015 01/28/2019 II/III 01/30/2014 01/04/2016 II 11/15/2019 II 07/24/2017 III 12/20/2019 I/II 12/02/2019 III 08/26/2015 II 06/11/2014 N/A 02/07/2017 I/II 12/28/2017 02/26/2019 N/A

Page 8 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Can CMV Dextramers be used to Monitor Anti-CMV Immunity After Allogeneic Hematopoietic Cell Transplantation A Comparison of Two Methods for Quantification of CMV-Specific T Cells by Flow Cytometry: HLA- Tetramers Versus HLA- Dextramers The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency A Pilot Study Evaluating NFAT, NFkB and, ERK 1/2 Nuclear Translocation as a Predictive Marker for Acute Graft-versus-Host Disease A Preliminary Study to Determine the Effect of Donor and Recipient Vaccinations on Clinical and Laboratory Outcomes after Autologous and Allogeneic Hematopoietic Cell Transplant (A221504) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL (ADENOCARCINOMA) (E4512 )A randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) (S1900) A Master protocol to Evaluate Biomarker-Driven Therapies and in Previously-Treated Non-Small Cell Lung Cancer (LungMap screening Study A Phase II Randomized Study of Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) (S1400) A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-Ablative Radiation to One or More of the Target Lesions in Patients with Stage IV NSCLC (CASE 1516) A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia (EQ001-aGVHD-001) A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects with Newly Diagnosed Acute Graft Versus Host Disease RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC) Cell Banking and Distribution of Leftover Human Biospecimens in the cGMP TCPF for Research Purposes (12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas Pilot Study: Assess the Impact on Patient Experience With Curbell's Rego Patient Interactive Device

Page 9 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Unknown Sites I-37216 Dean G Unknown Sites I-59817 Dean G Unknown Sites I-80418 Dean G Unknown Sites I-68318 Devonish J Unknown Sites I-77418 Devonish J Unknown Sites I-290516 Dexter E Lung NCG-263714 Dy G Lung NCG-263814 Dy G Lung N-68818 Dy G Lung NCG-290116 Dy G Lip, Oral Cavity and Pharynx; Lung I-286816 Dy G Lung I-257814 Dy G Lung I-281616 Dy G Multiple Sites P-37416 Dy G Multiple Sites P-70918 Dy G

Lung PH-290316 Dy G Multiple Sites P-54317 Dy G Multiple Sites P-73318 Dy G Multiple P-82519 Dy G

Page 10 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

01/24/2017 N/A 03/27/2018 01/10/2020 N/A 07/02/2019 N/A 08/30/2018 N/A 01/17/2019 Early Phase I 01/05/2017 03/06/2019 N/A 01/13/2015 III 01/13/2015 III 08/27/2018 07/02/2019 II 10/04/2016 09/25/2019 III 12/22/2016 I/II 06/29/2015 06/10/2019 II 06/29/2017 I/II 06/07/2017 02/08/2019 I 01/31/2019 I

07/20/2017 03/05/2019 II 08/27/2018 I 05/30/2019 I 10/08/2019 I

Page 11 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Moral Distress in Nurses providing direct patient care on inpatient oncology units and outpatient clinics RE-AIMing Nurses for Sleep Screening, Brief Intervention and Referral to Treatment (Sleep-SBIRT) Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors Health Promotion in African American Cancer Survivors: Feasibility Research (National Witness Project's Witness Role Models) Health Promotion in African American Cancer Survivors: Pilot Implementation Research (National Witness Project® Witness Role Models Use Precision Nutrition) Patient Survey of Referral from One Surgeon to Another to Reduce Maximum Waiting Time for Elective Surgery and Decrease Hours of Over-Utilized Operating Room Time (A081105) Randomized Study of or Observation in Patients with Completely Resected Epidermal Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (EA5162) Phase II Study of AZD9291 () in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR (EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Therapy in Patients with Advanced NSCLC or Squamous Head and Neck Cancer A Phase II Randomized, Double-Blind, Placebo- Controlled Study Evaluating Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing Chemoradiation Therapy A Phase I/II Open-Label Study of Nimotuzumab in Combination with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer (SCRX001-006) An Open-Label Study of in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors AMG 510 20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100). A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) First-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax-AXL-ADC) in patients with solid tumors A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion-Positve Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination with in Subjects with

Page 12 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Hodgkin's Lymphoma; Multiple Sites P-40516 Dy G Lung P-61618 Dy G Lung P-53917 Dy G Breast I-60517 Edge S Multiple Sites I-32316 Ernstoff M Melanoma, Skin N-42416 Ernstoff M Melanoma, Skin N-84019 Ernstoff M Other Skin I-50417 Ernstoff M Multiple Sites P-78818 Ernstoff M Multiple Sites PH-285316 Ernstoff M Multiple Sites P-61718 Ernstoff M Melanoma, Skin P-54117 Ernstoff M Multiple P-34516 Ernstoff M Colon I-63518 Erwin D Multiple P-40016 Fabiano A Brain and Nervous System I-286416 Fenstermaker R Brain and Nervous System I-259614 Fenstermaker R Brain and Nervous System NCG-253514 Fitzpatrick L Multiple Sites I-57917 Foster B Colon I-274515 Fountzilas C

Page 13 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

04/12/2018 I 10/19/2018 II 08/22/2018 02/07/2020 II 02/06/2019 N/A 11/15/2016 I 04/14/2017 II 06/24/2019 II 11/05/2018 III 07/03/2019 I 11/21/2016 I 09/11/2018 I/II 03/09/2018 12/09/2019 II 05/23/2017 04/05/2019 I 05/01/2019 N/A 04/07/2017 N/A 09/15/2016 N/A 05/04/2015 03/06/2018 II 02/21/2014 10/26/2018 II 07/03/2018 N/A 08/05/2016 10/22/2019 I/II

Page 14 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

of MEDI5395 in Combination with Durvalumab in Subjects with Select Advanced Solid Tumors A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anit-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with a PD-1 Inhibitor in Patients with Non-Small Cell Lung Cancer Breast Cancer Pathways Impact on Patient Shared Decision Making and Experience in Academic and Community Practice (CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm (S1512) A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM) (S1801) A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant (Anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases (Adjuvant Avelumab in MCC (ADAM) Trial (ALKS 4230-001) A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001) A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY -1 A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma MM-310-01-01-01: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors Increasing access and developing predictors for colorectal cancer screening for minority and Medicaid clients Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice Non-Therapeutic Exploratory Study of Serum Molecular Markers in Brain Tumor Patients Undergoing Surgical Resection of their Tumors A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma (COG ACNS1123) Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) Clinical Proteomics Tumor Analysis Consortium (CPTAC) Phase III Research Protocol A Phase Ib/II Study of and Pembrolizumab in Metastatic Colorectal Cancer

Page 15 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Colon I-265514 Fountzilas C Colon; Rectum I-444019 Fountzilas C Colon I-49617 Fountzilas C Stomach P-58917 Fountzilas C

Multiple Sites P-75218 Fountzilas C

Multiple Sites P-55217 Fountzilas C Pancreas P-57317 Fountzilas C Multiple Sites P-73818 Fountzilas C Multiple Sites PH-258614 Fountzilas C Multiple Sites PH-278115 Fountzilas C Multiple Sites; Pancreas P-71518 Fountzilas C Multiple P-60917 Fountzilas C Multiple Sites P-46317 Fountzilas C Pancreas P-75018 Fountzilas C Multiple PH-269015 Fountzilas C Breast N-61317 Fung-Kee-Fung S

Breast N-79418 Fung-Kee-Fung S Breast I-61918 Gandhi S Breast I-68018 Gandhi S Breast I-62218 Gandhi S

Page 16 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

05/08/2015 07/12/2017 I/II 11/08/2019 II 05/15/2018 II 01/23/2019 III

11/05/2019 II

03/30/2018 03/31/2019 I 10/26/2018 12/05/2019 I 02/12/2019 I 10/03/2014 I 06/07/2016 I 03/06/2019 I/II 11/15/2018 10/08/2019 I/II 01/04/2019 II 07/24/2019 III 10/30/2015 05/06/2019 I/II 04/20/2018 III

11/07/2018 II 04/24/2019 II 02/12/2019 II 01/09/2019 II

Page 17 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer A Phase II Study of TAS-102, Irinotecan and in Pre-treated Metastatic Colorectal Cancer (TABAsCO) (ACCRU-GI-1617) MOUNTAINEER: A Phase II, Open Label Study of Combined with in Patients with HER2+ Metastatic Colorectal Cancer (ISN 8951-CL-0301) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (8951-CL-5201): A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 BGB-A317 in combination with the PARP inhibitor BGB-290 in Subjects with Advanced Solid Tumors A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without in the Treatment of First-Line Metastatic A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (POD1UM-102) A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma A Phase IB/2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumors PUMA-NER-5201, An Open-Label, Phase 2 Study of in Patients With Solid Tumors With Somatic Human Epidermal (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer (NSABP B-51) A Randomized Phase III Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer A randomized phase II study to evaluate efficacy of TDM1with or without in the treatment of patients with metastatic HER2 positive breast cancer Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer

Page 18 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Melanoma, Skin I-53217 Gandhi S Breast I-73718 Gandhi S Multiple Sites P-74818 Gandhi S Multiple Sites P-41416 Gandhi S Breast I-36416 Gaudioso C Kidney NCG-242013 George S Prostate NCG-252514 George S Kidney I-145208 George S Bladder I-40216 George S Kidney I-191711 George S Multiple P-59517 George S Kidney P-39016 George S Kidney P-42016 George S Kidney P-51917 George S Kidney P-65318 George S Multiple Sites P-38516 George S Kidney P-38916 George S Bladder; Kidney P-70518 George S Kidney P-54217 George S Bladder P-53117 George S

Page 19 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

01/31/2018 I/II 12/06/2019 II 08/01/2019 I 08/10/2017 I/II 12/28/2016 11/13/2019 N/A 12/02/2013 07/16/2014 II 02/16/2015 08/31/2016 III 10/29/2009 11/11/2015 I/II 12/20/2018 II 10/05/2012 I/II 03/04/2019 08/05/2019 III 09/14/2017 II 11/29/2017 III 12/18/2018 01/28/2019 III 11/20/2018 09/09/2019 II 08/04/2017 I 09/18/2017 06/12/2019 III 05/20/2019 II 06/13/2018 06/18/2019 II 08/29/2018 10/10/2019 I/II

Page 20 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma Phase I Clinical Trial Assessing the Combination of Chemokine Modulation with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid Tumors Elderly Breast Patient Cohort Database (A031203) Randomized Phase II Study Comparing (NSC #761968 and IND #116059) with Commercially Supplied in Patients with Previously Untreated Locally Advanced or Metastatic (ALLIANCE A031201) Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone, and Prednisone for Castration Resistant Metastatic Prostate Cancer Phase I / II Study of High Dose 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma Phase II trial of Concurrent Nivolumab in UroThelial with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA] A Phase I/ II Trial of Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients An Open-Label, Randomized Phase 3 Study to Evaluate vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC) A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcino A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of in Combination With or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti-PD-a/ PD-L1 Based Immunotherapy A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with treatment A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES

Page 21 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Multiple P-57417 George S Unknown Sites I-63018 Glaser K Lung P-76718 Goniewicz M Lung I-70618 Goniewicz M Other Female Genital I-59317 Goniewicz M Unknown Sites P-522019 Goniewicz M Soft Tissue N-69118 Grand'Maison A Soft Tissue I-56317 Grand'Maison A Multiple Sites; Soft Tissue P-541719 Grand'Maison A

Multiple Sites P-37116 Grand'Maison A Soft Tissue P-43317 Grand'Maison A Myeloid and Monocytic Leukemia I-54017 Griffiths E Leukemia, other PH-213112 Griffiths E Myeloid and Monocytic Leukemia I-49217 Griffiths E Leukemia, other P-65918 Griffiths E Other Hematopoietic; Leukemia, other P-483719 Griffiths E Leukemia, other P-519719 Griffiths E Myeloid and Monocytic Leukemia; Leukemia, P-55117 Griffiths E other Prostate P-78418 Griffiths E Other Hematopoietic P-78518 Griffiths E

Page 22 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

04/17/2018 I 05/23/2018 N/A 11/27/2018 N/A 08/30/2018 N/A 08/21/2018 N/A 11/15/2019 N/A 12/21/2018 01/29/2019 I/II 07/30/2018 II 12/16/2019 N/A

07/28/2017 12/21/2018 II 11/20/2017 04/17/2019 III 10/17/2017 N/A 04/22/2013 N/A 03/27/2018 I 01/29/2019 06/05/2019 III 11/07/2019 N/A 12/17/2019 N/A 05/07/2018 01/29/2019 III

11/25/2019 I/II 02/28/2019 06/20/2019 I

Page 23 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

SGN22E-002 A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer Understanding health behaviors and perceptions of cancer in non-English speaking populations CONNECT (Clinical Outcomes of Nationwide, Naturalistic E-Cig Trial) Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous "switching" between flavors (CRoFT_3.1) Electronic Cigarette Use During Pregnancy International E-cigarette Study - Youth (A091304) A PHASE I/RANDOMIZED PHASE II STUDY OF MLN0128 (TAK-228) VS. PAZOPANIB IN PATIENTS WITH LOCALLY ADVANCED/UNRESECTABLE AND/OR METASTATIC SARCOMA A Non-Randomized, Open-Label, Phase 2 Study of in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma (DCC-2618) PROTOCOL DCC-2618-99-001 EXPANDED ACCESS PROGRAM FOR RIPRETINIB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GIST WHO HAVE RECEIVED TREATMENT WITH PRIOR THERAPIES A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion- Positive Tumors (LOXO-TRK-15002) 105SAR301, A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS); Evaluation of antibody response to high-dose seasonal influenza vaccination in patients with myeloid malignancy receiving chemotherapy Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) given with Adjuvant Poly-ICLC in Conjunction with 5-Aza-2'deoxycytidine (Decitabine) and Nivolumab in Patients with MDS or Low Blast Count AML (APL2-302) A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies ASTX727-02: A Phase 3, Randomized, Open-Label Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

A randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) A Phase Ib Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX727 (Cedazuridine and Decitabine) in Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia

Page 24 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Other Hematopoietic PH-289716 Griffiths E Unknown Sites I-67818 Grimmer J Bladder I-258714 Guru K Kidney I-53605 Guru K Prostate I-198211 Guru K Unknown Sites I-241913 Guru K Unknown Sites I-244113 Guru K Bladder I-53017 Guru K Unknown Sites I-77518 Guru K Prostate I-77718 Guru K Unknown Sites I-43217 Guru K Unknown Sites I-80918 Guru K Bladder P-48517 Guru K Unknown Sites I-41716 Hahn T Unknown Sites I-71018 Hanif A Colon I-44817 Haring R Unknown Sites I-281315 Haring R Unknown Sites I-62618 Haring R Lung I-62305 Hennon M Non-Hodgkin's Lymphoma I-38216 Hernandez F Non-Hodgkin's Lymphoma I-42804 Hernandez F Leukemia, other; Non-Hodgkin's Lymphoma CIC-01-16 Hernandez F

Page 25 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

05/12/2017 06/05/2019 III 03/21/2019 N/A 10/01/2015 N/A 04/14/2005 N/A 09/13/2011 N/A 07/17/2013 N/A 07/01/2014 N/A 03/01/2018 N/A 10/19/2018 11/19/2019 N/A 01/09/2019 N/A 08/07/2017 11/19/2019 N/A 05/31/2019 N/A 03/30/2018 II 02/24/2017 01/14/2019 N/A 11/28/2018 09/10/2019 N/A 06/15/2017 N/A 05/04/2016 03/02/2019 N/A 06/19/2018 N/A 07/26/2005 N/A 05/01/2017 N/A 02/11/2005 N/A 08/24/2001 N/A

Page 26 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents Routine nurse-led follow up in a chronic cancer pain management clinic for patients started on adjuvant neuropathic pain medications: Are patient outcomes improved? Assessment of Circulating Tumor Cells in Blood and Irrigation Fluid During Robot-Assisted Radical Cystectomy Kidney Cancer Database and Use of Existing Tissue Resources 1983-Present Prostate Cancer Database: Clinical Parameters Pilot: Evaluation and Assessment of Cognition During Robot Assisted Surgery Observational Study to Identify Patterns in Communication and Team Interaction in the Operating Room Spatial Analysis of Bladder Cancer in Western New York Art in the Workplace Impact of a National Comprehensive Cancer Network Compliant Multidisciplinary Consortium on Treatment Decisions in Patients with Localized Prostate Cancer Art Heals Does increased mobility assessed with 3D motion tracking technology lead to early post-operative recovery among patients undergoing oncologic surgeries CA-ALT-803-01-16 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer Risk Scoring in BMT Patients using PT Assessment/ variables to predict outcomes Improving Sign-Out Process between Medicine Services at Roswell Park Comprehensive Cancer Center Screen to Save: NCI Colorectal Cancer Screening Initiative, Clinical Trial Education and Outreach Finding a Pathway for Pathways: Intervention Dissemination in the Native American Landscape and Beyond Strengthening knowledge for future generations: Cancer bio-banks in the landscapes of the Haudenosaunee Lung Bronchoscopy Research Samples & Database Biomarkers of response to biological agents and/or chemotherapy agents in relapsed/refractory diffuse large B-cell lymphoma patients Evaluation of Changes in The Structure of CD20 and Downstream Signaling in Patients with Resistant/Refractory B-Cell Lymphomas and Leukemia Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum

Page 27 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma I-81718 Hernandez F Non-Hodgkin's Lymphoma I-46917 Hernandez F Non-Hodgkin's Lymphoma I-240813 Hernandez F Lymphoid Leukemia; Non-Hodgkin's Lymphoma I-69018 Hernandez F Non-Hodgkin's Lymphoma I-201611 Hernandez F

Multiple P-35616 Hernandez F Non-Hodgkin's Lymphoma P-70318 Hernandez F Non-Hodgkin's Lymphoma P-55917 Hernandez F

Non-Hodgkin's Lymphoma P-45017 Hernandez F Non-Hodgkin's Lymphoma P-56917 Hernandez F Lip, Oral Cavity and Pharynx I-281415 Hicks W Hodgkin's Lymphoma NCG-95706 Higman M Hodgkin's Lymphoma NCG-270515 Higman M Multiple Sites I-66418 Hillengass J Multiple Myeloma N-73218 Hillengass J Multiple Myeloma I-70118 Hillengass J Multiple Myeloma; Other Hematopoietic P-432519 Hillengass J

Multiple Myeloma P-72318 Hillengass J

Multiple Sites I-44417 Ho C

Page 28 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

04/22/2019 II 08/11/2017 02/06/2020 I 04/17/2014 I 03/08/2019 I 12/07/2011 11/14/2017 II

12/22/2017 I/II 05/30/2019 III 01/14/2019 06/03/2019 III

04/06/2018 05/24/2019 III 02/01/2019 I 04/05/2016 N/A 12/27/2006 04/10/2015 N/A 05/22/2015 08/02/2019 III 03/04/2019 N/A 10/31/2018 I/II 09/05/2019 N/A 12/10/2019 I

06/14/2019 09/11/2019 III

08/03/2017 I/II

Page 29 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(EDDOP NCI 10089) A Randomized Phase 2 Study of CDX-1127 () in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas (NCI 9930) A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL) Phase I/Ib Study of Carfilzomib plus Rituximab plus Ifosfamide plus plus (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma (ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM) (GO39942) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R- CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (PCYC-1141-CA) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects with Relapsed and/or Refractory B Cell Lymphoma Clinical and Pathological Prognosticators of Incidence, Progression and Survival in Head and Neck Cancers and Indications and Outcomes of Cancer-Related Plastic/Reconstructive Surgery (COG AHOD04B1/chob 2172) Hodgkin Disease Banking Study (COG AHOD1331) A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults Characterization of Focal Lesions in Monoclonal Plasma Cell Disorders over the Course of the Disease (A061202) A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy Feasibility of Strength Training and Impact on Pain and Quality of Life in Patients with Multiple Myeloma A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

A Phase 3 Study Comparing , VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation

Page 30 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Breast I-50317 Hydeman J Unknown Sites I-254814 Hyland A Unknown Sites I-47205 Hyland A Other Digestive Organ I-287016 Iyer R Multiple I-70218 Iyer R Liver P-81518 Iyer R Pancreas N-74618 Iyer R Multiple N-83019 Iyer R Liver I-56817 Iyer R Multiple I-64518 Iyer R Liver I-35316 Iyer R Pancreas I-259114 Iyer R Other Endocrine System; Multiple Sites I-79518 Iyer R Multiple Sites I-248813 Iyer R Multiple Sites I-235913 Iyer R Multiple P-47317 Iyer R Soft Tissue N-65118 Kane J Melanoma, Skin I-215912 Kane J Hodgkin's Lymphoma N-529719 Kelly K Lymphoid Leukemia I-48717 Kelly K Lymphoid Leukemia I-43517 Kelly K

Page 31 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

12/13/2017 N/A 04/22/2014 03/05/2019 N/A 02/03/2005 01/07/2019 N/A 08/22/2016 06/27/2019 N/A 11/05/2018 N/A 05/20/2019 N/A 10/31/2018 III 04/30/2019 III 06/11/2018 03/14/2019 I 06/17/2019 II 09/13/2017 I/II 05/15/2015 09/12/2017 II 06/13/2019 I 01/08/2015 01/25/2019 I 09/17/2013 I 06/01/2018 10/31/2019 I 02/27/2019 I 03/26/2013 I 12/20/2019 III 08/29/2017 Early Phase I 09/01/2017 III

Page 32 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients Examining Marketing and Promotion of Tobacco Products in Western New York Tobacco Retail Outlets Evaluation & Quality Assurance of the New York State Smokers' Quitline Immune Changes in Patients with Biliary Cancer and Correlation with Outcomes Roswell Park Neuroendocrine Tumor Biobank (19244); REFINE: observational study in hepatocellular carcinoma (A021602) RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON EVEROLIMUS (CABINET) (SWOG S1815) A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Phase I study of stereotactic body radiotherapy (SBRT) followed by nivolumab or ipilimumab with nivolumab in unresectable hepatocellular carcinoma Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin A Phase Ib/ II Study of and Pembrolizumab in Advanced Hepatocellular Cancer (HCC) Multicenter Phase II Study of Nintedanib for Patients with Advanced Carcinoid Tumors A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs) A Phase I Study of (LDK378), a Novel ALK Inhibitor, in Combination with Gemcitabine-Based Chemotherapy in Patients with Advanced Solid Tumors A Phase 1 Trial of CBL0137 in Patients with Metastatic or Unresectable Advanced Solid (I137-101) PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS (NRG-DT001) A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS) A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma (S1826) A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (NCT03907488) Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Page 33 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Non-Hodgkin's Lymphoma P-39216 Kelly K

Unknown Sites I-270915 Kisailus A Prostate N-509819 Kuettel M Prostate NCG-126608 Kuettel M Breast NCG-42404 Kuettel M Breast NCG-52305 Kuettel M Prostate NCG-83006 Kuettel M Prostate RTOG-P-0126 Kuettel M Esophagus I-283516 Kukar M Unknown Sites I-268815 Lau J Multiple Myeloma I-239513 Lee K Multiple Myeloma I-47217 Lee K Multiple Myeloma I-247913 Lee K Multiple Myeloma P-58817 Lee K Multiple Myeloma PH-278915 Lee K Other Female Genital; Ovary N-64218 Lele S Corpus Uteri NCG-163209 Lele S Other Female Genital; Ovary NCG-163309 Lele S Corpus Uteri N-19-04242 Lele S Other Female Genital; Ovary N-55817 Lele S

Page 34 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

09/29/2017 II

12/28/2015 N/A 12/16/2019 II 07/30/2008 08/12/2014 III 03/28/2005 02/02/2007 III 06/03/2005 11/24/2008 III 08/28/2006 11/06/2009 III 07/02/2002 08/20/2008 III 12/30/2016 II 06/05/2015 N/A 09/25/2015 03/14/2016 N/A 06/25/2018 II 03/09/2016 I 06/25/2018 I 01/18/2017 12/31/2019 III 01/24/2019 01/09/2020 N/A 03/23/2010 02/04/2013 III 02/12/2010 11/30/2011 III 05/16/2019 06/17/2019 II 03/08/2018 III

Page 35 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. The Impact of Summer Research Experience Programs on Preparing and Encouraging High School, Undergraduate and Medical Students for Advanced Education and Careers in Cancer Research NRG-GU007; Randomized Phase II trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in Higher Risk Prostate Cancer (with Initial Phase I) (RTOG 0534) A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (Spport) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy (CTSU NCIC CTG - MA 20) A Phase III Study of Regional Radiation Therapy in Early Breast Cancer (RTOG 0413) A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (RTOG 0415) A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Convestionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer Phase III randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II) Platelets in Extrinsic Glycosylation The Effect of Bortezomib on Antibody Titers Against Common Viral and Vaccine Antigens Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185) (EAE161) Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma (GOG 0249) A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma (GOG 0252) A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC#704865, IND#7921) NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent , and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. (NRG-GY006) A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer

Page 36 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Other Female Genital; Ovary N-65418 Lele S Ovary N-71218 Lele S

Other Female Genital; Cervix Uteri N-80018 Lele S Other Female Genital; Ovary N-33516 Lele S Other Female Genital; Ovary P-38316 Lele S

Breast P-48217 Levine E Breast N-41116 Levine E Multiple N-465919 Levine E Bladder N-58417 Levine E Bladder N-78918 Levine E Breast NCG-245113 Levine E Multiple Sites NCG-275215 Levine E Brain and Nervous System NCG-275515 Levine E

Breast CALGB-49909 Levine E Breast NCG-14703 Levine E Brain and Nervous System N-76518 Levine E Unknown Sites N-41616 Levine E

Breast NCG-82606 Levine E Kidney NCG-87906 Levine E

Page 37 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

10/29/2018 I/II 12/07/2018 II/III

04/08/2019 I 03/15/2017 II/III 02/16/2018 03/08/2019 III

07/23/2018 N/A 03/14/2017 III 10/07/2019 II 03/01/2018 III 03/28/2019 II 04/08/2014 III 06/01/2016 N/A 05/31/2016 III

01/19/2001 04/30/2005 III 12/02/2003 04/30/2010 III 07/09/2019 III 03/29/2017 05/07/2019 N/A

02/08/2007 08/20/2010 III 01/09/2007 09/01/2010 III

Page 38 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(NRG-GY007) A Phase I/II Study of with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY009) A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB IN PLATINUM RESISTANT OVARIAN CANCER (NRG-GY017) Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer NRG-GYN 005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer YO39523 / GOG-3015: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) (A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Asprin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial (A031702) Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors (A031501) Phase III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation (A031701) A Phase II Study of Dose-Dense Gemcitibine Plus Cisplatin (DDGC) in patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH) (A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women with HER-2 Overexpressing Node Positive or High Risk Node-negative Breast Cancer (CTSU IBCSG 24-02) A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women and Endocrine Responsive Breast Cancer (COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (EAQ152): COMET - Communication and Educ tion in Tumor Profiling:A Randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling (ECOG PACCT-1) Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial E2805 ASSURE Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Page 39 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Prostate NCG-89106 Levine E Breast NCG-275315 Levine E Breast N-431719 Levine E Breast N-50117 Levine E Breast N-78718 Levine E

Breast NCG-275415 Levine E Breast NCG-101907 Levine E

Breast NCG-181310 Levine E Breast N-41216 Levine E Breast NCG-81106 Levine E Breast N-32716 Levine E Bladder NCG-186610 Levine E Prostate NCG-237213 Levine E Breast NCG-250513 Levine E Breast I-55417 Levine E Breast P-51217 Levine E Multiple Sites P-39816 Levine E Bladder N-47717 Li Q

Bladder N-67218 Li Q Other Female Genital; Other Male Genital I-265614 Mahoney M

Page 40 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

02/27/2007 11/21/2012 III 09/09/2016 III 07/08/2019 III 07/27/2017 II 11/28/2018 04/01/2019 III

03/03/2016 III 07/27/2007 01/06/2010 III

07/13/2011 01/22/2013 III 04/17/2017 III 04/18/2007 02/01/2010 III 02/02/2017 06/15/2019 III 02/28/2011 12/02/2014 III 07/05/2013 07/15/2017 III 03/13/2014 07/15/2019 III 10/15/2018 II 01/08/2018 III 05/25/2017 N/A 09/27/2017 07/05/2019 II

11/05/2018 III 01/06/2015 03/06/2019 N/A

Page 41 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(ECOG E3805) CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial of Extensive Disease in Prostate Cancer (EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/ with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer," (NCT03199885) NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery (NSABP B-55/BIG 6-13) A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NSABP B-42) A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (NCIC CTG MA.32) A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Nepadjuvant Chemotherapy (SWOG S0307) Phase III Trial of Biphosphonates as Adjuvant Therapy for Primary Breast Cancer S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Metastases (CALGB 90601) A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (SWOG S1216) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (Alliance A011106) ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN) Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial) (S1605) Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

(S1602) A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer Understanding Factors Impacting HPV Vaccination: A Environmental Scan

Page 42 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Lung I-46817 Mahoney M Other Hematopoietic I-57217 McCarthy P Other Hematopoietic NCG-00403 McCarthy P Leukemia, other NCG-202611 McCarthy P Non-Hodgkin's Lymphoma N-32016 McCarthy P Multiple N-429819 McCarthy P I-78618 McCarthy P Unknown Sites RP-99-05 McCarthy P Lymphoid Leukemia; Non-Hodgkin's Lymphoma P-80318 McCarthy P Unknown Sites I-62918 McKinney M Multiple Sites I-78218 Mohler J Prostate I-278515 Mohler J Prostate P-42116 Mohler J Breast; Stomach I-79218 Moon W Ovary EPR-01103 Moysich K Esophagus I-42917 Mukherjee S Colon N-59217 Mukherjee S Anus N-68518 Mukherjee S Anus I-76618 Mukherjee S Colon N-60617 Mukherjee S

Esophagus; Stomach I-443819 Mukherjee S

Page 43 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

05/24/2017 Early Phase I 04/18/2019 Early Phase I 03/28/2003 N/A 10/19/2011 N/A 04/14/2017 III 09/11/2019 N/A 12/19/2019 II 08/16/1999 II 02/27/2019 N/A 05/06/2018 06/30/2019 N/A 06/06/2019 N/A 07/26/2016 02/08/2019 Early Phase I 08/10/2017 III 02/07/2019 N/A 05/20/2003 N/A 12/06/2017 07/18/2019 N/A 04/26/2018 III 12/22/2018 II 12/13/2018 II 06/27/2018 08/09/2019 III

12/10/2019 II

Page 44 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

EVarQuit: Extinguishing cigarette smoking via extened pre-quit varenicline A Pilot Study generating a biorepository to correlate Bio Markers and outcomes of Cellular Therapy Patients Center for International Blood and Marrow Transplant Research Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries (CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications A051301/BMT CTN 1201; A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype (BMTCTN 1702) Clinical Transplant - Related Long-term Outcomes of ALthernative Donor ALlogenic Transplantation ( CTRL-ALT-D) A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss -Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release Clinical Trial and Enrollment & Oncology Pathways (2018-01) Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Comparing Unilateral and Bilateral Deep Inferior Epigastric Perforators (DIEP) Flaps for unilateral breast reconstruction Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer Comparing the Molecular Characteristics and Therapeutic Responses of Esophageal Adenocarcinoma with Corresponding Patient Derived Models (A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch (EA2165) A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (NCI 9673) Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Amendment) (NRG-GI004/SWOG-S1610) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevaczumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Use of Trifluridine/tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and gastroesophageal junction (GEJ) adenocarcinoma

Page 45 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Colon I-52917 Mukherjee S Colon P-44317 Mukherjee S Colon; Rectum P-63218 Mukherjee S Prostate I-285716 Nastiuk K Colon I-65518 Noyes E Unknown Sites I-72518 O'Connor R Unknown Sites I-80518 O'Connor R Unknown Sites I-225912 O'Connor R Unknown Sites I-68718 O'Connor R Breast I-225312 O'Connor R Unknown Sites I-471719 O'Connor R Unknown Sites I-285916 O'Connor R Unknown Sites I-50217 O'Connor R Unknown Sites I-51517 O'Connor R Unknown Sites I-59617 O'Connor R Breast N-80218 O'Connor R Breast N-30716 O'Connor R Breast I-32816 O'Connor R Breast I-67518 O'Connor R Multiple Sites I-215512 Odunsi K Multiple Sites I-226412 Odunsi K Multiple Sites P-54517 Odunsi K

Page 46 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

03/27/2018 II 10/12/2017 04/05/2019 III 11/21/2019 II/III 09/21/2017 N/A 10/19/2018 N/A 08/29/2019 N/A 09/19/2019 N/A 10/23/2012 03/11/2019 N/A 10/23/2018 N/A 04/18/2013 03/12/2019 N/A 10/07/2019 N/A 06/21/2016 Early Phase I 07/18/2017 N/A 07/19/2017 N/A 04/03/2018 N/A 12/26/2018 II 01/26/2017 III 10/06/2017 N/A 11/09/2018 N/A 02/14/2014 N/A 02/14/2014 N/A 06/06/2018 N/A

Page 47 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Phase 2A Study Evaluating a Chemokine-Modulatory Regimen in Patients with Colorectal Cancer Metastatic to the Liver A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC). (IS0-CC-007): A Randomized, Multicenter, Parallel-Group, Phase III Study To Compare The Efficacy Of Arfolitixorin Versus Leucovorin In Combination With 5 Fluorouracil, Oxaliplatin, And Bevacizumab In Patients With Advanced Colorectal Cancer Alteration of Serum Cytokines During ADT in Treatment-Naive Prostate Cancer Patients Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC Methods for characterizing flavor impact on user behavior and perceptions Consumer assessment of tobacco flavor and odor Behavioral Intention to Use Tobacco Products: Effect and Affective, Cognitive, and Sensory Factors Effects of filter ventilation on sensory response, smoking topography, and inhalation (COMET 2 2.1) Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults Nicotine Vapor Specific Sensory Measurement Pilot Studies of Functional Near Infrared Spectroscopy in Behavioral and Communications Research Semi structured interviews for assessing tobacco packaging (COMET 2 1.1) Impact of Menthol Delivery Methods on Smoker Sensory Perceptions Effects of package color and descriptors on tobacco product perceptions (COMET 2 1.2) (A171601) A PHASE II TRIAL ASSESSING THE TOLERABILITY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors: A Feasibility Pilot Trial Exercise and Nutrition Intervention in Older Breast Cancer Survivors Analysis of Tumor Antigens, Immunity, and Genetic Changes in Gynecological Cancer Patients NY-ESO-1 Expression in Patients with Solid Tumors (ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Page 48 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Multiple P-81418 Odunsi K Other Female Genital; Ovary I-45717 Odunsi K Unknown Sites I-56117 Odunsi K Other Female Genital; Ovary NCG-64705 Odunsi K

Ovary I-285416 Odunsi K Soft Tissue P-39716 Odunsi K Brain and Nervous System N-83219 Twist C Ovary I-287616 Odunsi K

Other Female Genital; Ovary I-248613 Odunsi K

Ovary I-283616 Odunsi K Other Female Genital; Ovary I-288216 Odunsi K Multiple Sites I-258514 Odunsi K Other Female Genital; Ovary I-43717 Odunsi K Multiple P-54617 Odunsi K Multiple P-35216 Odunsi K Multiple Sites P-49417 Opyrchal M Unknown Sites I-44717 Pailler M Liver I-287116 Petroziello M Unknown Sites I-45417 Platek M

Page 49 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

03/12/2019 N/A 04/12/2018 N/A 06/13/2018 N/A 01/12/2006 01/13/2014 III

10/10/2017 I/II 10/04/2017 I/II 06/25/2019 II 01/24/2019 I

08/01/2014 01/02/2020 I/II

12/08/2017 I 06/29/2017 I/II 06/30/2017 I/II 11/06/2017 Early Phase I 05/14/2019 02/12/2020 I 03/21/2017 I/II 12/02/2017 08/12/2019 I 05/31/2017 02/14/2019 N/A 08/30/2016 N/A 05/23/2017 N/A

Page 50 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

3D Prediction of Patient-specific Response using Ex vivo Interrogation of Live Cells from Tumors TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE The GYN Molecular Information Registry (GOG 0212) A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel Or CT-2103 (IND #70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy NCI EDDOP #10017, A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies (COG ACNS1721) A Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High Grade (HGG) without H3K27M or BRAFV600 Mutations A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) after a Myeloablative Conditioning Regimen, with Administration of IL-2 in Patients with Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory Ovarian Cancer A Phase I/II Evaluation of Olaparib in combination with Durvalumab and in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a Germline BRCA1 or BRCA2 Mutation A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell in Patients with Advanced Malignancies A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer Phase 1 dose escalation, multi-tumor study to assess the safety, tolerability and antitumor activity of genetically engineered MAGE-A4c1032T in HLA-A2+ subjects with MAGE-A4 positive tumors (ADP-0044-001) A multinational, open-label, dose escalation Phase I Study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009) "Talking Pictures": An exploratory study of meaning-based social media intervention for Adolescent and Young Adult cancer patients Radiation-Emitting SIR-Spheres in Non-Resectable (RESiN) Liver Tumor Patient Study Understanding the Prevalence of Malnutrition Risk Among Cancer Patients Undergoing Radiation Treatment at RPCI

Page 51 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Lung I-208611 Pokharel M Breast N-41516 Prasad D Myeloid and Monocytic Leukemia P-72918 Przespolewski A Myeloid and Monocytic Leukemia P-51717 Przespolewski A Myeloid and Monocytic Leukemia P-69618 Przespolewski A Lymphoid Leukemia; Other Skin I-56717 Puzanov I Multiple Sites N-45117 Puzanov I Melanoma, Skin N-59417 Puzanov I Multiple I-291016 Puzanov I Multiple Sites; Pancreas P-73618 Puzanov I Multiple Sites; Non-Hodgkin's Lymphoma P-66118 Puzanov I

Melanoma, Skin PH-285216 Puzanov I Multiple P-43117 Puzanov I Melanoma, Skin P-44617 Puzanov I Melanoma, Skin P-39116 Puzanov I Other Skin P-75918 Puzanov I Multiple PH-290916 Puzanov I

Melanoma, Skin P-47916 Puzanov I Multiple P-51817 Puzanov I

Page 52 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

04/24/2012 N/A 09/12/2017 09/12/2019 II 08/16/2019 I/II 10/19/2018 05/29/2019 II 04/23/2019 III 08/17/2018 II 06/30/2017 I/II 04/05/2018 II 01/22/2018 I/II 02/07/2019 I 01/17/2019 I

08/23/2017 02/04/2019 I/II 08/29/2017 04/17/2019 I 10/12/2017 11/15/2019 I/II 08/17/2018 II 03/06/2019 II 05/09/2017 01/10/2020 I/II

04/06/2018 II 09/07/2018 I

Page 53 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

European Thoracic Oncology Platform (ETOP) Lungscape Master Protocol (RTOG 1119) Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent in Patients with Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute Myeloid Leukemia who are 60 Years or Older - The BATTLE Study (GMI-1271-301) A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia NCI 10057: A Phase II Study of talimogene laherparepvec (T-VEC) Followed by talimogene laherparepvec (T-VEC) + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors (S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (SWOG S1616) A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of (ADCT-301) in Patients With Selected Advanced Solid Tumors CPI-006-001 A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD 73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (DV3-MEL-01) A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma A Phase 1b Study of Intratumoral IMO 2125 in Patients with Refractory Solid Tumors (2125-RST-101) 2125-204, A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma IMCgp100-202, A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma Study 16-214-02 (Combination): A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES A Multicenter Phase 2, Adaptive, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, As a Single Agent or in Combination With Nivolumab, Ipilimumab, or Docetaxel in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)

Page 54 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Unknown Sites I-60717 Quinn T Unknown Sites I-75418 Quisenberry A Unknown Sites I-475819 Quisenberry A Lung I-217812 Reid M Lung I-251914 Reid M Lung I-96706 Reid M Unknown Sites I-50017 Rodriguez E Unknown Sites NCG-246313 Rokitka D Non-Hodgkin's Lymphoma NCG-256514 Rokitka D Brain and Nervous System N-56017 Rokitka D Other Male Genital N-80818 Rokitka D Unknown Sites NCG-139608 Rokitka D Unknown Sites NCG-164809 Rokitka D Unknown Sites NCG-51505 Rokitka D Kidney POG-8158 Rokitka D Kidney POG-9442 Rokitka D Unknown Sites I-34216 Rokitka D Unknown Sites I-186310 Rokitka D Lymphoid Leukemia N-58317 Rokitka D Other Respiratory and Intrathoracic Organs NCG-287516 Rokitka D Soft Tissue NCG-260314 Rokitka D Unknown Sites I-69418 Rokitka D

Page 55 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

08/28/2018 N/A 10/01/2018 N/A 12/31/2019 N/A 01/16/2013 N/A 04/09/2014 N/A 02/07/2007 N/A 08/25/2017 N/A 11/14/2013 N/A 01/16/2015 03/02/2018 N/A 01/17/2018 N/A 01/30/2019 N/A 09/22/2008 N/A 01/29/2010 N/A 05/03/2005 N/A 10/01/1986 10/01/1995 N/A 05/22/1995 N/A 03/16/2017 N/A 05/20/2011 N/A 01/31/2018 N/A 09/21/2016 II 04/23/2015 01/22/2019 II/III 01/18/2019 N/A

Page 56 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial: Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability Pharmacokinetics, subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or unflavored e-liquids [SALTVAPE Study] Detection of Early Lung Cancer Among Military Personnel Study 1(DECAMP-1): Diagnosis and Surveillance of Indeterminate Pulmonary Nodules with a Civilian Expansion:ACRIN 4703 Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients at High Risk for Developing Lung Cancer with a Civilian Expansion The Stacey Scott Lung Cancer Registry Understanding the cancer prevention educational needs of the Western New York Puerto Rican Hispanic Population: Puentes a Esperanza y Vida (Translated: Bridges to Hope and Life) (COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy (COG ALTE11C1) Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma ALTE 15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study (ALTE16C1) Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma (COG ALTE05N1/ DB 2518) Umbrella Long-Term Follow-Up Protocol (COG ALTE07C1, CHOB 2563) Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer (ALTE03N1/ CHOB 2519) Key Adverse Events Following Childhood Cancer National Wilms' Tumor Long-Term Survivors' Study, A Non-Therapeutic Study. (CHOB 291) National Wilms Tumor # 5: Late Effects Study 2016 National AYA Patient and Survivor Survey Examining Quality of Life Among Long-Term Survivors of Childhood Cancer (ALTE1631) A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia (COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial (NRG/COG ARST1321) Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) Aromatherapy: An Integrative Option for Symptom Management in Cancer Care

Page 57 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Unknown Sites I-70718 Schierer S Unknown Sites I-64918 Sheffer C Lung I-65718 Sheffer C Breast I-72218 Sheffer C Lung I-82819 Sheffer C Multiple I-290616 Sherrow C Lip, Oral Cavity and Pharynx I-49117 Singh A Lip, Oral Cavity and Pharynx; Esophagus N-505719 Singh A Multiple N-66918 Singh A Lip, Oral Cavity and Pharynx N-61217 Singh A Multiple I-56617 Singh A Lip, Oral Cavity and Pharynx I-48917 Singh A Lung I-124407 Singh A Lung I-50717 Singh A Lip, Oral Cavity and Pharynx I-61117 Singh A Multiple Sites I-81318 Singh A Lung I-81919 Singh A Multiple Sites I-60017 Skitzki J Multiple Sites I-65618 Stewart E Prostate I-44117 Sumlin A Prostate I-76918 Sumlin A

Page 58 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

10/23/2018 I 06/21/2018 N/A 09/04/2018 N/A 01/16/2019 N/A 05/03/2019 N/A 10/12/2016 N/A 02/12/2018 10/02/2019 N/A 11/01/2019 II/III 06/10/2019 II 04/04/2019 II/III 06/18/2018 N/A 04/02/2018 Early Phase I 09/12/2008 04/15/2015 II 12/18/2017 Early Phase I 05/03/2018 II 11/18/2019 III 11/06/2019 I 07/01/2019 I 08/03/2018 01/10/2020 N/A 08/29/2017 N/A 01/04/2019 N/A

Page 59 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Effects of Physical Distraction and Music on Anxiety during Wide Local Excision Evaluation of Roswell Park Cessation Services Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation Enhancing a home-based walking intervention among breast cancer survivors with rTMS: Feasibility and limited efficacy testing Promising methods to decrease delay discounting and reduce relapse to smoking Conventional vs iPad-based Education for Gastrointestinal Cancer Patients Undergoing Chemotherapy: A Non-Interventional Study Validation of a mobile imaging system for oral cancer screening in low resource settings in EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) (NRG-HN004) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin A Pilot Study of Photoacoustic Imaging (PAI) A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node Negative, Peripheral Non-Small Cell Lung Cancer Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer A Randomized, Open-Label Study to Assess the Pain, Toxicity and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated with Chemoradiation for Head and Neck Cancer A Phase 2 Randomized Study with a non-Randomized Cohort: Assessing Single-fraction SBRT versus STandard PalliativE Radiation In Patients with Metastatic Disease (ASTEROID) A Feasibility and Toxicity Analysis of Single Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer A Single-center Phase I Dose Escalation/Response Trial to Evaluate the Safety, Tolerability, and Anti-tumor Efficacy of Intra-arterial CBL0137 for Patients with Advanced Extremity Melanoma or Sarcoma Understanding the relationship of caregiver stress to perceived preparedness for prescribed tasks and responsibilities caring for patients undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CS+HIPEC) Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection The Impact of Financial Distress on Prostate Cancer Treatment: A Feasibility Study

Page 60 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Other Hematopoietic N-83919 Sundaram S Multiple N-19-04141 Sundaram S Lymphoid Leukemia; Non-Hodgkin's Lymphoma P-82619 Sundaram S Non-Hodgkin's Lymphoma P-59017 Sundaram S Breast I-63718 Takabe K Breast P-49517 Takabe K Bladder I-255514 Tang L Other Hematopoietic NCG-288816 Thompson J Myeloid and Monocytic Leukemia P-46017 Thompson J Myeloid and Monocytic Leukemia N-79018 Thompson J Myeloid and Monocytic Leukemia P-46117 Thompson J Myeloid and Monocytic Leukemia I-67118 Thota S Non-Hodgkin's Lymphoma N-62718 Torka P Multiple Myeloma P-57517 Torka P Non-Hodgkin's Lymphoma P-66518 Torka P Hodgkin's Lymphoma P-49917 Torka P

Non-Hodgkin's Lymphoma P-33116 Torka P Unknown Sites I-217912 Travers M Unknown Sites I-106907 Travers M Brain and Nervous System COG-ANBL00B1 Twist C

Page 61 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

04/22/2019 III 06/21/2019 III 10/23/2019 I/II 08/29/2018 01/02/2020 II 08/17/2018 N/A 11/09/2018 II 07/01/2014 02/05/2020 N/A 01/06/2017 N/A 09/27/2017 01/27/2020 N/A 12/19/2018 II 05/01/2018 10/17/2019 III 12/02/2019 II 07/10/2019 III 02/08/2019 07/24/2019 I/II 04/11/2019 II 04/02/2018 03/29/2019 III

05/18/2017 03/06/2019 I/II 08/07/2012 N/A 07/20/2007 N/A 04/17/2001 N/A

Page 62 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(A041702) A Randomized Phase III Study of Ibrutinib Plus Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age)With Chronic Lymphocytic Leukemia EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) (UTX-TGR-205) A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin¿s Lymphoma Global Identification of Cancer Biology in the Tumors of Primary or Metastatic Breast Cancer An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women with Primary Nonrecurrent Breast Cancer Undergoing Surgery Diet and Lifestyle in a Prospective Study of Bladder Cancer Survivors The National Myelodysplastic Syndromes (MDS) Study Observational Study Protocol CA180653: Determining change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States (S1712) A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease CABL001A2301; A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors A Phase II Study of Intensive Salvage Therapy Followed by for Patients with AML Harboring Mutations in IDH2 who have Failed or been Refractory to Frontline Therapy (EA4151) A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission (M15-654) A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma A Phase II Study of Palbociclib (PD-0332991) in Combination with Ibrutinib in Patients with Previously Treated Mantle Cell Lymphoma (CA209-812) Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812) An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Evaluating Tobacco Product Displays in the Retail Environment Evaluation of Smoker Reactions to Novel Tobacco Products (CHOB 665) Neuroblastoma Biology Studies

Page 63 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Lymphoid Leukemia NCG-44704 Twist Kidney NCG-77006 Twist C Lymphoid Leukemia NCG-95606 Twist C Lymphoid Leukemia NCG-182410 Twist C Non-Hodgkin's Lymphoma NCG-214712 Twist C Unknown Sites NCG-279615 Twist C Brain and Nervous System N-479919 Twist C Multiple Sites N-52617 Twist C Multiple Sites N-52817 Twist C Multiple Sites N-55017 Twist C Multiple N-55017-SC Twist C Lymphoid Leukemia N-56517 Twist C Lymphoid Leukemia N-57617 Twist C Lymphoid Leukemia N-57717 Twist C Brain and Nervous System N-58017 Twist C Brain and Nervous System N-71718 Twist C Liver N-74918 Twist C Hodgkin's Lymphoma NCG-02503 Twist C Soft Tissue NCG-107407 Twist C Lymphoid Leukemia; Leukemia, other NCG-108507 Twist C Kidney NCG-118507 Twist C Multiple Sites; Soft Tissue NCG-141708 Twist C

Page 64 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

01/24/2005 06/07/2010 N/A 05/30/2006 N/A 01/05/2007 07/16/2018 N/A 10/20/2010 07/16/2018 N/A 04/06/2012 12/08/2017 N/A 03/09/2016 N/A 12/10/2019 II 11/09/2017 III 11/28/2017 II 01/09/2018 N/A 01/09/2018 II 12/20/2018 II 04/04/2018 III 01/30/2018 Early Phase I 01/31/2018 II 07/18/2018 III 10/11/2018 II/III 04/11/2003 10/06/2009 III 08/17/2007 02/10/2012 III 03/10/2008 07/25/2014 III 12/10/2007 05/24/2013 III 11/18/2008 05/17/2013 III

Page 65 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(COG AALL03B1/CHOB 984) Classification of Acute Lymphoblastic Leukemia (COG AREN03B2/CHOB 2061) Renal Tumors Classification, Biology and Banking Study (COG AALL05B1/chob 2197) A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens (COG AALL08B1) Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (COG ANHL04B1) Rare and Cutaneous Non-Hodgkin Lymphoma Registry (COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study A Phase 2 Randomized Study of Irinotecan/Temozolomide/ with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors (APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) (APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL (AALL1621) A Phase 2 Study of (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing in Combination with Two Different Cytotoxic Chemotherapy Backbones AALL15P1A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement ACNS 1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients (ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) (COG AHODOO31/CHOB 805) A Phase III Group-Wide Study of Dose Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate-Risk Hodgkin Disease (COG ARST0332/ CHOB 2230) Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age (COG AALL0434/ CHOB 2360) Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-Cell Lymphoblastic Lymphoma (COG AREN0533/CHOB 2296) Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors (COG ARST0531/CHOB 2492) Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)

Page 66 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Brain and Nervous System NCG-186710 Twist C Lymphoid Leukemia NCG-206911 Twist C Multiple Sites; Non-Hodgkin's Lymphoma NCG-221412 Twist C Non-Hodgkin's Lymphoma NCG-263314 Twist C Soft Tissue NCG-270415 Twist C Brain and Nervous System NCG-272315 Twist C Lymphoid Leukemia NCG-273015 Twist C Myeloid and Monocytic Leukemia NCG-274715 Twist C Myeloid and Monocytic Leukemia NCG-289616 Twist C Soft Tissue NCG-290716 Twist C

Lip, Oral Cavity and Pharynx NCG-41204 Twist C Lymphoid Leukemia NCG-53705 Twist C Lymphoid Leukemia NCG-56005 Twist C Brain and Nervous System NCG-63405 Twist C Kidney NCG-88906 Twist C Myeloid and Monocytic Leukemia NCG-92806 Twist C Lymphoid Leukemia POG-9904 Twist C Lymphoid Leukemia POG-9905 Twist C Lymphoid Leukemia PH-286916 Twist C Multiple Myeloma; Leukemia, other CALGB-8461 Wang E

Page 67 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

12/10/2010 05/28/2019 III 05/07/2012 08/09/2019 III 10/03/2012 02/09/2016 II/III 12/03/2014 05/24/2019 III 07/17/2015 03/20/2019 III 06/19/2015 III 09/13/2016 09/27/2019 III 11/18/2015 05/07/2019 III 02/13/2017 III 02/08/2018 III

11/23/2004 09/23/2011 III 05/23/2005 01/28/2011 III 07/13/2005 05/28/2010 III 10/25/2005 07/31/2015 III 12/26/2006 11/27/2013 II 01/04/2007 06/15/2010 III 08/03/2000 04/15/2005 III 08/03/2000 04/15/2005 III 09/08/2017 II 08/20/1984 12/01/2015 N/A

Page 68 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years (COG AALL1131) A Phase III Randomized Trial for Newly Diagnosed High Risk BLymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations) (COG ANHL1131) Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients (COG AALL1231) A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) (COG AEWS1221) Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma (COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma (COG AALL1331) Risk-Stratified Randomized Phase III Testing of (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) (COG AAML1331) A Phase III Study For Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid (COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome (COG ARST1431) A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (COG ARST0331/CHOB 957) Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma (COG AALL0232/CHOB 1043) High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) (COG AALL0331/CHOB 1049) Standard Risk-B Precursor Acute Lymphoblastic Leukemia (COG ANBL0032/DB 2497) Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue (COG AREN0321/CHOB 2112) Treatment of High Risk Renal Tumors (COG AAML0531/CHOB 2279) A Phase III Randomized Trial of (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults (CHOB 590) ALinC17: Treatment for Patients with Newly Diagnosed Low Risk Acute Lymphoblastic Leukemia (CHOB 591) ALINC #17: Protocol for Patients with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia Cytogenic Studies in Acute Leukemia and Multiple Myeloma

Page 69 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Myeloid and Monocytic Leukemia CALGB-9760 Wang E Myeloid and Monocytic Leukemia I-32616 Wang E Lymphoid Leukemia P-32516 Wang E Lymphoid Leukemia N-57017 Wang E Lymphoid Leukemia NCG-260214 Wang E Lymphoid Leukemia NCG-269115 Wang E

Myeloid and Monocytic Leukemia P-36216 Wang E Multiple P-71318 Wang E Myeloid and Monocytic Leukemia; Leukemia, P-73018 Wang E other Myeloid and Monocytic Leukemia P-52217 Wang E Myeloid and Monocytic Leukemia P-53517 Wang E Myeloid and Monocytic Leukemia P-31316 Wang E Myeloid and Monocytic Leukemia; Leukemia, P-58117 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-66618 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-30816 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-50917 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-66718 Wang E other

Page 70 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

07/11/1997 01/15/2011 N/A 08/28/2017 03/14/2019 I 03/30/2017 N/A 08/20/2018 III 06/30/2015 10/15/2019 III 03/08/2016 II

01/10/2018 02/25/2019 III 03/15/2019 I 06/06/2019 I

09/11/2018 III 11/01/2018 III 06/15/2017 II/III 12/11/2018 I

03/01/2019 I

09/19/2017 04/08/2019 I

05/11/2018 I

08/30/2019 I/II

Page 71 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Multidrug Resistance Studies in Acute Leukemia Immune Monitoring During ASP2215 Therapy in Relapsed/Refractory Acute Myeloid Leukemia An Observational Study of Patients with Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US (A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone,Vincristine,Methotrexate,6 Mercaptopurine) for Pts >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Neg (Ph-) ALL and of Dasatinib (NSC 732517) , Prednisone and Blinatumomab for Pts >/= 65 Years of Age with Newly Diagnosed Ph+ ALL, Relapsed/Refractory Ph+ ALL, and Ph-Like Signature ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF) AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Phase 1/1b Open-Label, Dose-Escalation Study of APVO436 in Patients with Relapsed or Refractory AML or High-Grade MDS

(ARO-021) Phase III Randomized Study of versus Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia (ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy A PHASE 1 DOSE ESCALATION STUDY OF DS-3032B, AN ORAL MDM2 INHIBITOR, AS SINGLE AGENT AND IN COMBINATION WITH 5-AZACITIDINE IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

A Phase 1 Study of Milademetan in combination with in subjects with FLT3 ITD mutant Acute Myeloid Leukemia that are relapsed/refractory, or newly diagnosed and unfit for intensive chemotherapy

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

Page 72 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Myeloid and Monocytic Leukemia P-57117 Wang E Myeloid and Monocytic Leukemia PH-280115 Wang E Leukemia, other P-46517 Wang E Multiple Sites PH-283416 Wang E Myeloid and Monocytic Leukemia P-84119 Wang E Multiple P-71418 Wang E

Myeloid and Monocytic Leukemia; Leukemia, P-45917 Wang E other Myeloid and Monocytic Leukemia P-53317 Wang E Myeloid and Monocytic Leukemia; Leukemia, P-53417 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-46617 Wang E other Myeloid and Monocytic Leukemia; Leukemia, P-51017 Wang E other Myeloid and Monocytic Leukemia P-59717 Wang E

Melanoma, Skin I-287416 Wooten K Lung P-55717 Yau E

Multiple Sites I-66018 Yendamuri S Lung I-72818 Yendamuri S

Page 73 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

07/11/2018 I 10/05/2016 06/27/2019 I 08/24/2018 II 11/04/2016 11/22/2019 I/II 09/04/2019 I 08/15/2019 III

02/23/2018 09/19/2019 I

09/11/2018 10/08/2019 I 09/20/2018 03/01/2019 I

01/10/2018 I/II

03/21/2018 01/06/2020 II

01/04/2019 I/II

09/15/2016 N/A 08/05/2019 II

02/07/2019 N/A 01/22/2019 N/A

Page 74 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies A Phase 1, Multi-Center, Open-Label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies (KO-MEN-001) A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO 539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia A Phase 3, Randomized, Open-label, Multicenter Study Comparing versus Imatinib, Administered in Combination with Reduced-intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)(Ponatinib- 3001) (ONO-7475-01) A Phase I open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias

A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with MCL-1 Dependence 30% TROV-052-A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML) Treatment Outcomes in Cutaneous Melanoma of the Head and Neck (CA-ALT-803-02-17) QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination with Pembrolizumab or Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer who have Disease Progression Following an Initial Response to Treatment with PD-1 Checkpoint Inhibitor Therapy Endoscopy Sample Collection Protocol Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer

Page 75 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

Lung P-445719 Yendamuri S Breast NCG-266014 Young J Corpus Uteri; Ovary I-37616 Zsiros E Other Female Genital; Ovary I-61818 Zsiros E Unknown Sites I-65018 Zsiros E Ovary I-45817 Zsiros E Cervix Uteri P-38016 Zsiros E

Page 76 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

12/17/2019 II 09/08/2015 02/19/2019 III 12/12/2016 N/A 03/22/2018 N/A 06/06/2018 N/A 06/27/2017 06/10/2019 II 07/07/2017 II

Page 77 of 78 09/28/2021 Current Active Clinical Trials - Roswell Park Cancer Institute

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST) (A211102) Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Life On The Go 1: Evaluating the Effect of Baseline Physical Activity of Patients with Endometrial and Ovarian Cancer using State of the Art Activity Tracking Device Opioid Use in Post-operative Gynecologic Oncology Patients Evaluation of Burnout and Wellness Among Gynecologic Oncology Fellows Nationwide Life On The Go 2: Evaluating the Effect of Physical Activity of Patients with Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

Page 78 of 78 09/28/2021